Chemokine 12 plasma level in pediatric patients with Immune Thrombocytopenic purpura and its relation to Disease Activity

Taha, Gamal Eldin Mohamed; Ahmed, Aya Badawi; Mabrouk, Amna Gouda; Abdel Kader, Noha Abdel Hafeez

doi:10.21608/ejmr.2022.240191

Chemokine 12 plasma level in pediatric patients with Immune Thrombocytopenic purpura and its relation to Disease Activity

Document Type : Original Article

Authors

¹ Pediatric department, Faculty of Medicine,,Beni-Suef University, Beni-Suef

² Pediatric department, Faculty of Medicine, Beni-Suef University, Beni-Suef

³ Clinical pathology department, Faculty of Medicine, Beni-Suef University, Beni-Suef

10.21608/ejmr.2022.240191

Abstract

The goal of this study was to investigate a possible association of chemokine 12 plasma level and its association to ITP , This was a prospective, observational, case-control study which was conducted on 60 patients with ITP with age ranging from 1 -18 years old together with 90 healthy controls. The plasma level of chemokine 12 in pediatric ITP patients and healthy controls were determined using enzyme linked immunosorbent assay (ELISA) The detection limit for this assay was 1.5 pg per ml. Patients were subjected also to lab investigation in the form of CBC and BM aspirate and There was a high plasma level of chemokine 12 in cases than controls (p value <0.05). Furthermore, cases with high plasma level of chemokine 12 were more susceptible for steroid dependency than controls (p < 0.05) otherwise, no significant differences between plasma level of chemokine 12 among cases as regard clinical picture , history data , ITP course.

Keywords

Main Subjects

Diagnostic

References

Kashiwagi, Hirokazu, and Yoshiaki Tomiyama "Pathophysiology and management of primary immune thrombocytopenia." International journal of hematology 98.1 (2013): 24-33.
Nomura S. "Advances in diagnosis and treatments for immune thrombocytopenia." Clinical Medicine Insights: Blood Disorders, (2016) 9: 15.
Neunert C, Lim W, et al. "The American Society of Hematology evidence-based practice guideline for immune thrombocytopenia." J. Blood 117(16): 4190-4207(2011).
Bavunoğlu, Işıl, Bavunoğlu I , Ar MC , Cengiz M , Yavuzer S , Salihoğlu A , Öngören Ş , Tunçkale A , Soysal T , "Treatment of patients with immune thrombocytopenia admitted to the emergency room." International journal of hematology 104.2 (2016): 216-222.
Schulze H, Gaedicke G. "Immune thrombocytopenia in children and adults: What’s the same, what’s different?" J.Haematologica. (2011);96:1739–1741.
Johnsen, Jill. "Pathogenesis in immune thrombocytopenia: new insights." ASH Education Program Book 2012.1 (2012): 306312.
Bussel J.B, Miguel P.G, Despotovic J.M , Grainger J.D, Sevilla, Blanchette V.S," Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, "placebo-controlled study.Lancet Haematol, 2 (2015), pp. e315-e325 .
D’Orazio, John A, et al. "ITP in children: pathophysiology and current treatment approaches." Journal of pediatric hematology/oncology 35.1 (2013): 1-13.
Rodeghiero,Francesco,RodeghieroF^., MichelM, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, Cines DB, Cooper N, Godeau B, Greinacher A, Imbach P, Khellaf M, Klaassen RJ, KühneT, LiebmanH, MazzucconiMG, NewlandA, PabingerI, Tosetto A, Stasi R, "Standardization of bleeding assessment in immune thrombocytopenia"report from the International Working Group" J Blood (2013).
Zufferey A, Kapur R, Semple JW. "Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)" Journal of clinical medicine, (2017).
Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek F, Jansen A."Emerging Concepts in Immune Thrombocytopenia. Frontiers in immunology, (2018).
Bussel JB, et al." International consensus report on the investigation and management of primary immune thrombocytopenia".journal Blood (2010); 115:168–186.
Wu KH, Peng CT, Li TC, Wan L, Tsai CH, Tsai J. "Interleukin-1beta exon 5 and interleukin-1 receptor antagonist in children with immune thrombocytopenic purpura" J Pediatr Hematol Oncol. (2007);29:305- 308.
Faraj S , Ghali H. "Immune Thrombocytopenia Purpura, Experience of Single Institute", (2019) Wasit, Iraq.
Ahmed Alhammadi, Shabina Khan, Najla Ba Sharahil, Rasha Qaqish, Boudoor Alshamiri, Yasmine Sobeih, Yaslam Balfaqih^" Epidemiological And Clinical Feature of Newly Diagnosed Childhood Immune Thrombocytopenic Purpura in Qatar"j qscience , Qatar Foundation Annual Research Conference Proceedings Volume 2016 Issue 1, Mar( 2016).
George JN, Woolf SH, Raskob GE, et al." Idiopathic thrombocytopenic purpura" A practice guideline developed by explicit methods for the American Society of Hematology.j Blood (1996), 88: 3–40.
Evim MS, BirolBaytan, and Adalet MeralGüneş." Childhood Immune Thrombocytopenia": Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura .(2014) Mar; 31(1): 32–39.
Jung, J. Y, Kim J. K, Park M." Clinical course and prognostic factors of childhood immune thrombocytopenia" single center experience of 10 years. Korean journal of pediatrics, 59(8), 335–340 (2016).